- Home
- SNDX
as 04-18-2025 1:43pm EST
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 974.9M | IPO Year: | 2016 |
| Target Price: | $36.20 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.66 - $25.07 | Next Earning Date: | 05-07-2025 |
| Revenue: | $23,680,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 286.51% | Revenue Growth (next year): | 120.86% |
Stock Insider Trading Activity of Syndax Pharmaceuticals Inc. (SNDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Metzger Michael A | SNDX | Chief Executive Officer | Mar 4 '25 | Sell | $15.05 | 7,814 | $117,563.97 | 300,121 | |
| Gallagher Neil | SNDX | President, Head of R&D | Feb 10 '25 | Sell | $15.50 | 4,618 | $71,597.47 | 85,095 | |
| Goldan Keith A. | SNDX | Chief Financial Officer | Feb 10 '25 | Sell | $15.50 | 3,777 | $58,558.61 | 90,746 | |
| Metzger Michael A | SNDX | Chief Executive Officer | Feb 10 '25 | Sell | $15.50 | 13,288 | $206,017.15 | 300,121 |
Latest Syndax Pharmaceuticals Inc. News
SNDX Breaking Stock News: Dive into SNDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
17 days ago
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
a month ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GuruFocus.com
a month ago
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...
MT Newswires
2 months ago
B. Riley Cuts Price Target on Syndax Pharmaceuticals to $29 From $36, Keeps Buy Rating
Zacks
2 months ago
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
MT Newswires
2 months ago
Syndax Pharmaceuticals Q4 Loss Widens
Associated Press Finance
2 months ago
Syndax: Q4 Earnings Snapshot
Compare SNDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.